{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0003","upperLimit":"0.0702","value":"0.013"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"}],"units":"Participants"}],"description":"The local failure rate within the high-risk HL participants treated with AEPA/CAPDac will be estimated with a 95% confidence interval using appropriate methods (e.g., estimate cumulative incidence in the presence of competing risks).","dispersionType":"95% Confidence Interval","groups":[{"description":"Ann Arbor stage IIB, IIIB, IVA, or IVB participants receive:\n\n2 cycles of AEPA chemotherapy:\n\n(A) Brentuximab vedotin 1.2 mg/kg IV (intravenous) days 1, 8 and 15, (E) Etoposide 125 mg/m\\^2 IV days 1-5, (P) Prednisone 60 mg/m\\^2/day PO (orally) days 1-15, (A) Doxorubicin 40 mg/m\\^2 IV days 1 and 15),\n\nFollowed by 4 cycles of CAPDac:\n\n(C) Cyclophosphamide 500 mg/m\\^2 IV days 1 and 8, (A) Brentuximab vedotin 1.2 mg/kg IV days 1 and 8, (P) Prednisone 40 mg/m\\^2/day PO days 1-15, (Dac) Dacarbazine 250 mg/m\\^2 IV days 1-3.).\n\nFilgrastim 5 mcg/kg subcutaneous (SC) as clinically indicated.\n\nFor those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy is given.","id":"OG000","title":"AEPA/CAPDac"}],"paramType":"NUMBER","populationDescription":"All the evaluable participants treated with AEPA/CAPDac.","reportingStatus":"POSTED","timeFrame":"From start of therapy to 2 years after completion of therapy (up to 3 years after study enrollment)","title":"Local Failure Rate in High Risk HL Patients Treated With AEPA/CAPDac.","type":"SECONDARY","unitOfMeasure":"Probability"}